Immunosuppressive therapy for multiple sclerosis

Neurologic Clinics

Volumn 23, Issue 1, 2005, Pages 247-272

  Gauthier, Susan A ^a   Buckle, Guy J ^a   Weiner, Howard L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; DACLIZUMAB; DOXORUBICIN; EPIRUBICIN; FOLIC ACID; GLATIRAMER; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ALLERGIC ENCEPHALITIS; ALOPECIA; AMENORRHEA; BLADDER DISEASE; BREAST CANCER; CANCER RISK; CARDIOTOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEART VENTRICLE ARRHYTHMIA; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; LEUKOPENIA; MENSTRUATION DISORDER; META ANALYSIS; MULTIPLE SCLEROSIS; NAUSEA; PRIORITY JOURNAL; REVIEW;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS;

EID: 12344335055     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2004.09.007     Document Type: Review

References (103)

1. R. Martin, H. McFarland, and D. McFarlin Immunological aspects of demyelinating diseases Annu Rev Immunol 10 1992 153 187
2. D. Hafler, and H. Weiner Immunologic mechanisms and therapy in multiple sclerosis Immunol Rev 144 1995 75 107
3. P. Conlon, J. Oksenberg, and J. Zhang The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system Neurobiol Dis 6 1999 149 166
4. H.L. Weiner A 21 point unifying hypothesis on the etiology and treatment of multiple sclerosis Can J Neurol Sci 25 1998 93 101
5. A. Windhagen, J. Newcombe, and F. Dangond Expression of co-stimulatory molecules B7-1(CD80), B7-2 (CD86),and interleukin 12 cytokine in multiple sclerosis lesions Exp Med 182 1995 1985 1996
6. C. Langford, J. Klippel, and J. Balow Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease: part 1. Rheumatologic and renal diseases Ann Intern Med 128 1998 1021 1028
7. C. Langford, J. Klippel, and J. Balow Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease: part 2. Inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity Ann Intern Med 129 1998 49 58
8. G. Aimard, P. Girard, and J. Raveau Multiple slerosis and autoimmunization process. Treatment by antimitotics Lyons Med 215 1966 345 352
9. H. Weiner, and J. Cohen Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects Mult Scler 8 2002 142 154
10. P. Girard, and H. Pellet Therapeutique immuno-depressive en neurogie Presse Med 75 1967 967 968
11. P. Millac, and H. Miller Cyclophosphamide in multiple sclerosis Lancet 1 1967 783
12. V.L. Weiczorek, and W. Brodkorb Erfahrungen mit der immunosuppressive behandlung der multiplen sklerose mit cyclophamid und imuran Disch Ges Wesen 26 1971 1791 1794
13. W. Gopel, H. Benkenstein, and M. Banzhaf Immunosuppressive therapy of multiple sclerosis using cyclophosphamide and imuran. Report on 57 cases Dtsch Gesundheitsw 27 1972 1955 1961
14. W. Cendrowski Combined therapeutic trial in multiple sclerosis: hydrocortisone hemisuccinate with cyclophosphamide or cytosine arabinoside Acta Neurol Belg 73 1973 209 219
15. D. Drachman, P. Paterson, and R. Schmidt Cyclophosphamide in exacerbations of multiple sclerosis. Therapeutic trial and a strategy for pilot drug studies J Neurol Neurosurg Psychiatry 38 1975 592 597
16. O. Hommes, J. Prick, and K. Lamers Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone Clin Neurol Neurosurg 78 1975 59 72
17. O. Hommes, K. Lamers, and P. Reekers Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis J Neurol 223 1980 177 190
18. O. Hommes, K. Lamers, and P. Reekers Prognostic factors in intensive immunosuppression on the course of chronic progressive multiple sclerosis 1980 Springer-Verlag Berlin p. 396-400
19. R.E. Gonsette, L. Demonty, and P. Delmotte Intensive immunosuppression with cyclophosphamide in multiple sclerosis. Follow up of 110 patients for 2-6 years J Neurol 214 1977 173 181
20. R.E. Gonsette, L. Demonty, and P. Delmotte Intensive immunosuppression with cyclophosphamide in remittent forms of multiple sclerosis: follow-up of 134 patients for 2-10 years Bauer H.J. Progress in multiple sclerosis research 1980 Springer-Verlag Berlin (Germany)
21. S. Hauser, D. Dawson, and J. Lehrich Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH N Engl J Med 308 1983 173 180
22. J.L. Carter, D.A. Hafler, and D.M. Dawson Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients Neurology 38 1988 9 14
23. D. Goodkin, S. Plencner, and J. Palmer-Saxerud Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy Arch Neurol 44 1987 823 827
24. H.L. Weiner, G.A. Mackin, and E.J. Orav Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group Neurology 43 1993 910 918
25. M. Hohol, M. Olek, and E. Orav Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease Mult Scler 5 1999 403 409
26. W. Likosky, B. Fireman, and R. Elmore Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study J Neurol Neurosurg Psychiatry 54 1991 1055 1060
27. The Canadian Cooperative Trial of Cyclophosphamide and Plasma Exchange in Progressive Multiple Sclerosis Lancet 337 1991 441 446
28. J. Noseworthy, G. Ebers, and R. Roberts Cyclophosphamide and MS Neurology 44 1994 579 581
29. H.L. Weiner, D.M. Dawson, and D.A. Hafler Cyclophosphamide and plasma exchange in multiple sclerosi Lancet 337 1991 1033 1034
30. J. Noseworthy, M.K. Vandervourt, and M. Penman Cyclophosphamide and plasma exchange in multiple sclerosis Lancet 337 1991 1540 1541
31. J. Killian, R. Bressler, and R. Armstrong Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis Arch Neurol 45 1988 27 30
32. F. D'Andrea, C. D'Aurizio, and C. Marini Cyclophosphamide in relapsing remitting multiple sclerosis Ital J Neurol Sci 11 1990 271 274
33. E. Millefiorini, M. Di Giovanni, and S. Bernardi 24-month follow-up of multiple sclerosis patients treated with cyclophosphamide Ital J Neurol Sci 11 1990 605 607
34. O. Khan, M. Zvartau-Hind, and C. Caon Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy Mult Scler 7 2001 185 188
35. M. Gobbini, M. Smith, and N. Richert Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis J Neuroimmunol 99 1999 142 149
36. F. Patti, M. Cataldi, and F. Nicoletti Combination of cyclophosphamide and interferon-beta halts progression in patients with rapidly transitional multiple sclerosis J Neurol Neurosurg Psychiatry 71 2001 404 407
37. P. Perini, and P. Gallo Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis J Neurol 250 2003 834 838
38. H. Zephir, J. De Seze, and A. Duhamel Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients J Neurol Sci 218 2004 73 77
39. Smith DR, Weinstock-Guttman B, Cohen JA, et al. Randomized trial of pulse cyclophosphamide therapy and interferon beta 1a in patients with active MS [abstract]. Presented at the annual meeting of the American Academy of Neurology. Hawaii, 2003.
40. P. Paterson, and D. Drobish Cyclophosphamide:effect on experimental allergic encephalomyelitis in Lewis rats Science 165 1969 191 192
41. D. Moody, J. Fahey, and E. Grable Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment J Neuroimmunol 14 1987 175 182
42. D. Moody, J. Kagan, and D. Liao Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters J Neuroimmunol 14 1987 161 173
43. D. Hafler, J. Orav, and R. Gertz Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis J Neuroimmunol 32 1991 149 158
44. M. Mickey, G. Ellison, and J. Fahey Correlation of clinical and immunological states in multiple sclerosis Arch Neurol 44 1987 371 375
45. D. Smith, K.E. Balashov, and D.A. Hafler Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia Ann Neurol 42 1997 313 318
46. M. Comabella, K. Balashov, and S. Issazadeh Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy J Clin Invest 102 1998 671 678
47. H. Takashima, D.R. Smith, and H. Fukaura Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients Clin Immunol Immunopathol 88 1998 28 34
48. A. Karni, K. Balashov, and W. Hancock Cyclophosphamide modulates CD4(+) T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8(+) T cells in secondary progressive multiple sclerosis J Neuroimmunol 146 2004 189 198
49. O. Hommes, F. Aerts, U. Bahr, and H. Schulten Cyclophosphamide levels in serum and spinal fluid of multiple sclerosis patients treated with immunosuppression J Neurol Sci 58 1983 297 303
50. U. Bahr, O. Hommes, and F. Aerts Determination of cyclophosphamide in urine, serum, and cerebrospinal fluid of multiple sclerosis patients by field desorption spectrometry Clin Chim Acta 103 1980 183 192
51. M. Wender, E. Tokarz, G. Michalowska, and A. Wajgt Therapeutic trials of multiple sclerosis and intrathecal IgG production Ital J Neurol Sci 7 1986 205 208
52. K. Lamers, B. Uitdehaag, and O. Hommes The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis J Neurol Neurosurg Psychiatry 51 1988 1334 1337
53. E. Portaccio, V. Zipoli, and G. Siracusa Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort Mult Scler 9 2003 446 450
54. D. Boumpas, H. Austin, and E. Vaughan Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy Ann Intern Med 119 1993 366 369
55. M. Gourley, H. Austin, and D. Scott Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial Ann Intern Med 125 1996 549 571
56. M.J. Moore Clinical pharmacokinetics of cyclophosphamide Clin Pharmacokinet 20 1991 194 208
57. C. Radis, L. Kahl, and G. Baker Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study Arthritis Rheum 38 1995 1120 1127
58. C. Talar-Williams, Y.M. Hijazi, and M.M. Walther Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis Ann Intern Med 124 1996 477 484
59. G. Ehninger, B. Proksch, and G. Heinzel Clinical pharmacology of mitoxantrone Cancer Treat Rep 70 1986 1373 1378
60. M. Crespi, S. Ivanier, and J. Genovese Mitoxantrone affects topoisomerase activities in human breast cancer cells Biochem Biophys Res Commun 136 1986 521 528
61. J. Fidler, S. DeJoy, and J.J. Gibbons Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function J Immunol 137 1986 727 732
62. J. Fidler, S. DeJoy, and F.R. Smith Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice J Immunol 136 1986 2747 2754
63. L.S. Rosenberg, M.J. Carvlin, and T. Krugh The antitumor agent mitoxantrone binds cooperatively to DNA: evidence for heterogeneity in DNA conformation Biochemistry 25 1986 1002 1008
64. L. Posner, G. Dukart, and J. Goldberg Mitoxantrone: an overview of safety and toxicity Invest New Drugs 3 1985 123 132
65. S. Levine, and A. Saltzman Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone J Neuroimmunol 13 1986 175 181
66. S.C. Ridge, A. Sloboda, and R. McReynolds Suppression of experimental allergic encephalomyelitis by mitoxantrone Clin Immunol Immunopathol 35 1985 35 42
67. F. Lublin, M. Lavasa, C. Viti, and R. Knobler Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone Clin Immunol Immunopathol 45 1987 122 128
68. C.M. Watson, A.N. Davison, and D. Baker Suppression of demyelination by mitoxantrone Int J Immunopharmacol 13 1991 923 930
69. G. Edan, D. Miller, and M. Clanet Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria J Neurol Neurosurg Psychiatry 62 1997 112 118
70. H. Hartung, R. Gonsette, and N. Konig Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial Lancet 360 2002 2018 2025
71. R. Gonsette, and L. Demonty Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients Neurology 40 Suppl 1 1990 261
72. L. Kappos, R. Gold, and E. Künstler Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-Enhanced MRI Neurology 40 Suppl 1 1990 261
73. E. Mauch, H. Kornhuber, and H. Krapf Treatment of multiple sclerosis with mitoxantrone Eur Arch Psychiatry Clin Neurosci 242 1992 96 102
74. H. Krapf, E. Mauch, and U. Fetzer Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone Neuroradiology 37 1995 113 119
75. J. Noseworthy, M. Hopkins, and M. Vandervoort An open-trial evaluation of mitoxantrone in the treatment of progressive MS Neurology 43 1993 1401 1406
76. S. Bastianello, C. Pozzilli, and F. D'Andrea A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year Can J Neurol Sci 21 1994 266 270
77. E. Millefiorini, C. Gasperini, and C. Pozzilli Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome J Neurol Sci 244 1997 153 159
78. F.A. Van de Wyngaert, C. Beguin, and M.B. D'Hooghe A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis Acta Neurol Belg 101 2001 210 216
79. M. Mustafa, P. Diener, and J. Sun Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity Scand J Immunol 38 1993 499 507
80. R. Ghalie, G. Edan, and M. Laurent Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS Neurology 59 2002 909 913
81. R. Ghalie, E. Mauch, and G. Edan A study of therapy-related acute leukemia after mitoxantrone therapy for multiple sclerosis Mult Scler 8 2002 441 445
82. R.E. Gonsette Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 206 2003 203 208
83. G. Dukart, and J. Barone An overview of cardiac episodes following mitoxantrone administration Cancer Treat Symp 3 1984 35 41
84. B. Foster, L. Lev, and C. Bermann Cardiac events in Phase II trials with mitoxantrone Cancer Treat Symp 3 1984 43 46
85. F. Mather, R. Simon, G. Clark, and D. Von Hoff Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies Cancer Treat Rep 71 1987 609 613
86. A. Aviles, N. Arevila, and J. Diaz Maqueo Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults Leuk Lymphoma 11 1993 275 279
87. J. Avasarala, A. Cross, and D. Clifford Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis Mult Scler 9 2003 59 62
88. C.A. Felix Secondary leukemias induced by topoisomerase-targeted drugs Biochem Biophys Acta 1400 1998 233 255
89. D. Brassat, C. Recher, and E. Waubant Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS Neurology 59 2002 954 955
90. D.E. Goodkin Therapy-related leukemia in mitozantrone treated patients Mult Scler 9 2003 426
91. C. Cattaneo, C. Almici, and E. Borlenghi A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis Leukemia 17 2003 985 986
92. D. Goodkin, R. Rudick, and S. VanderBrug-Medendorp Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis Ann Neurol 37 1995 30 40
93. P. Calabresi, J. Wilterdink, and J. Rogg An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS Neurology 58 2002 314 317
94. P.L. Yudkin, G.W. Ellison, and A.G. Ghezzi Overview of azathioprine treatment in multiple sclerosis Lancet 338 1991 1051 1055
95. G. Lus, F. Romano, and A. Scuotto Azathioprine and interferon beta (1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment Eur Neurol 51 2004 15 20
96. O. Fernandez, M. Guerrero, and C. Mayorga Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study J Neurol 249 2002 1058 1062
97. S. Markovic-Plese, B. Bielekova, and N. Kadom Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b Neurology 60 2003 1849 1851
98. N. Ahrens, A. Salama, and J. Haas Mycophenolate-mofetil in the treatment of refractory multiple sclerosis J Neurol 248 2001 713 714
99. Vukusic S, Ducray F, Gignoux L, et al. Mycophenolate mofetil: an open-label study in 42 MS patients [abstract]. Presented at the annual meeting of the American Academy of Neurology. San Francisco, 2004.
100. Vermersch P, Waucquier N, Bourteel H, et al. Treatment of multiple sclerosis with a combination of interferon beta-1a (Avonex) and mycophenolate mofetil (CellCept): results of a phase II clinical trial [abstract]. Presented at the annual meeting of the American Academy of Neurology. San Francisco 2004.
101. D. Goodkin, R. Kinkel, and B. Weinstock-Guttman A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis Neurology 51 1998 239 245
102. R. Zivadinov, R.A. Rudick, and R. De Masi Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS Neurology 57 2001 1239 1247
103. D. Miller, O. Khan, and W. Sheremata A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 2003 15 23